MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma

Ryoma Kurahashi,Tsuyoshi Kadomatsu,Masaya Baba,Chiaki Hara,Hitoshi Itoh,Keishi Miyata,Motoyoshi Endo,Jun Morinaga,Kazutoyo Terada,Kimi Araki,Masatoshi Eto,Laura S. Schmidt,Tomomi Kamba,W. Marston Linehan,Yuichi Oike

DOI: https://doi.org/10.1111/cas.14026

IF: 5.7

2019-05-24

Cancer Science

Abstract:<p>Xp11.2 translocation renal cell carcinoma (Xp11 tRCC) is a rare sporadic pediatric kidney cancer caused by constitutively active TFE3 fusion proteins. Tumors in patients with Xp11 tRCC tend to recur and undergo frequent metastasis, in part due to lack of methods available to detect early stage disease. Here we generated transgenic (Tg) mice overexpressing the human <i>PRCC‐TFE3</i> fusion gene in renal tubular epithelial cells, as an Xp11 tRCC mouse model. At 20 weeks of age, mice showed no histological abnormalities in kidney but by 40 weeks exhibited Xp11 tRCC development and related morphological and histological changes. miR‐204‐5p levels in urinary exosomes of 40‐week‐old Tg mice exhibiting tRCC were significantly elevated compared with levels in control mice. miR‐204‐5p expression also significantly increased in primary renal cell carcinoma cell lines established both from Tg mouse tumors and from tumor tissue from two Xp11 tRCC patients. All of these lines secreted miR‐204‐5p‐containing exosomes. Notably, we also observed increased miR‐204‐5p levels in urinary exosomes in 20‐week‐old renal <i>PRCC‐TFE3</i> Tg mice prior to tRCC development, and those levels were equivalent to those in 40‐week‐old Tg mice, suggesting that miR‐204‐5p increases follow expression of constitutively active TFE3 fusion proteins in renal tubular epithelial cells prior to overt tRCC development. Finally, we confirmed that miR‐204‐5p expression significantly increases in non‐cancerous human kidney cells after overexpression of a <i>PRCC‐TFE3</i> fusion gene. These findings suggest that miR‐204‐5p in urinary exosomes could be a useful biomarker for early diagnosis of patients with Xp11 tRCC.</p><p>This article is protected by copyright. All rights reserved.</p>

oncology